
Evaluation of an Enzyme Immunoassay Technique on Detecting Urinary Histoplasma capsulatum Antigen in the Diagnosis of Disseminated Histoplasmosis in Argentina and Comparison With Blood Polymerase Chain Reaction and Conventional Methods

[Emmanuel Marin](#)^{*}, [Fernando Messina](#), [Mercedes Romero](#), [Alicia Arechavala](#), [Roxana Depardo](#), [Gabriela Santiso](#)^{*}

Posted Date: 4 May 2023

doi: 10.20944/preprints202305.0224.v1

Keywords: histoplasmosis; Histoplasma antigen; Histoplasma diagnosis; Blood culture; Latin America.



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Evaluation of an Enzyme Immunoassay Technique on Detecting Urinary *Histoplasma capsulatum* Antigen in the Diagnosis of Disseminated Histoplasmosis in Argentina and Comparison with Blood Polymerase Chain Reaction and Conventional Methods

Emmanuel Marin *, Fernando A. Messina, Mercedes Romero, Alicia Arechavala, Roxana Depardo and Gabriela Santiso *

Unidad Micología, Hospital de Infecciosas F. J. Muñoz B.A. Uspallata 2272, C1282 Buenos Aires City, Argentina; emamarin@hotmail.com (E.M.); fmessina35@gmail.com (F.A.M.); mecharomero@gmail.com (M.R.); aliarecha@hotmail.com (AA); roxanadepardo@yahoo.com.ar (R.D.); santisogabi@gmail.com (GS)

* Correspondence: emamarin@hotmail.com; Tel+5492216024124 santisogabi@gmail.com Tel+5491140969543

Abstract: Histoplasmosis is a systemic mycosis of universal distribution, highly endemic in the Americas. It is caused by a dimorphic fungus *Histoplasma capsulatum* var. *capsulatum*. It affects both immunocompetent and immunocompromised individuals where progressive and disseminated forms are observed. A very important risk factor is HIV infection/AIDS, with a mortality rate of 20-40% in Latin America. The diagnosis of this mycosis is made by conventional and molecular methods or by antigen and antibody detection. This study evaluated the sensitivity and specificity of a commercial kit for the detection of *Histoplasma* antigen by an EIA (HC-Ag) technique in 50 patients with histoplasmosis associated with AIDS. In addition, its performance was compared with that of other diagnostic techniques routinely used in our laboratory. HC-Ag had a sensitivity (S) of 94%, specificity (E) 95.5%, positive predictive value (PPV) 94% and negative predictive value (NPV) 95.5%. The delay time of the results was 4 days, similar to that of antibody detection and n-PCR and much less than that of blood cultures. The combination of methods improved S and NPV: 100%; with similar values in E and PPV. The HC-Ag method demonstrated its usefulness in the diagnosis of progressive disseminated histoplasmosis and the combination of methods is a good option to increase sensitivity and decrease the time to reach the diagnosis of certainty. This allows improving the strategy in the management of the disease and decreasing its case-fatality rate.

Keywords: histoplasmosis; *Histoplasma* antigen; *Histoplasma* diagnosis; Blood Culture; HIV Infections; Latin America.

1. Introduction

Histoplasmosis (HP) is a cosmopolitan mycosis, endemic in the American continent, but with cases in the five continents. It is caused by the dimorphic fungus *Histoplasma capsulatum* var. *capsulatum* [1]. The areas of highest incidence lie along the valleys of the Ohio and Mississippi rivers in North America, in several countries of Central America as Guatemala, El Salvador and Panama [1,2] and in the basins of the Orinoco, Magdalena, Amazonas, San Francisco, Paraná and La Plata rivers in South America [3,4]. In Argentina, the main endemic area is the geographic region known as the Pampas and it is estimated that there are approximately seven million individuals infected with *H. capsulatum* [5]. HIV/AIDS associated histoplasmosis presents a prevalence of 2.5-5% [6-8] and it is the second potentially fatal systemic fungal infection in frequency [8].

Histoplasmosis can affect both immunocompetent and immunocompromised individuals. Clinical manifestations depend on the infecting strain [9,10], the fungal load and the immune status

of the patient [6,7]. A high risk of developing disseminated and progressive histoplasmosis exists in HIV/AIDS patients [11]. In Latin America the fatality rate ranges from 20 to 40% [2,12,13], higher than that of the United States, which ranges from 4 to 8% [14,15] and it is an AIDS marker disease in 30 to 75 % of cases [7,8,16–18].

Diverse studies have estimated that the incidence of histoplasmosis in Latin America could be 1.5 cases per 100 HIV+ per year; which would add about 22,000 cases and produce about 9000 deaths annually, this would be higher than annual deaths from tuberculosis [19,20]. Anyway, the real prevalence in our region remains unknown because it is not a communicable disease, and on the other hand in many countries diagnosis is deficient due to the lack of diagnostic tools [3,12,19].

Laboratory diagnosis of histoplasmosis is made through different techniques that can be classified into: (a) Conventional, (b) Molecular and (c) Immunological methods.

Conventional methods include microscopic observation and culture of various clinical samples. When patients present mucocutaneous manifestations, the diagnosis can be quickly performed by microscopic observation of *H. capsulatum* yeasts in Giemsa stained smears from scarifications or biopsies of such lesions; this technique has a variable sensitivity of 9-43% depending on the kind of lesion, the time of evolution and the operator expertise [21,22]. If the patients have no skin or mucocutaneous lesions culturing different clinical samples including lysis-centrifugation blood culture can be made. This technique can take up to 21 days for fungal growth and has about 70% sensitivity in HIV positive patients [21,23].

Molecular methods are based on different PCR techniques and have high sensitivity and specificity [24–26]. However, its main disadvantage is that there are still no validated and easily accessible commercial kits and reproducibility of home techniques is highly variable among laboratories and there is a lack of consensus for their application [27].

Antibody detection is an accessible immunological method but depends on the clinical form and the immunological status of the host. In AIDS associated histoplasmosis less than 30% of patients present detectable specific antibodies [23]. In contrast, detection of *H. capsulatum* galactomannan antigens in these cases is much more efficient and also allows monitoring the effectiveness of treatment [28,29]. The first methods for detecting *Histoplasma* antigens by enzyme immunoassays (EIA) were described in 1986 [30]. This technique was later adapted to using in urine and serum samples in 1994 [31], and currently there are commercial ELISA kits that use monoclonal antibodies such as HGM 101 (IMMY®, Norman, OK, USA) [32–34]. The latter gave very good results in a recent study carried out in Latin America, with very high sensitivity and specificity [35]. However, in our country it is still not used as a routine test due to its high cost. For this reason, its performance as a diagnostic method is unknown yet.

The objective of this study was to evaluate the sensitivity (S) and specificity (E) of the HGM201 kit for detecting *H. capsulatum* urinary antigen (HC-Ag) by EIA, to establish its usefulness in the early diagnosis of AIDS associated HP, and to compare its results with those of blood culture (BC), antibody detection (Ac -ID) and a PCR in blood (Hcp100 nPCR). Clinical and demographic characteristics of the studied patients were also analyzed.

2. Materials and Methods

Type of study

A retrospective longitudinal and analytical study was conducted between January 2019 and December 2020.

Demographic and clinical data as well as the results of diagnosis of proven disseminated and progressive histoplasmosis (PPDH) in HIV/AIDS patients were compared with those of HIV+ patients with other pathologies and a group of healthy volunteers, at the Mycology Unit of Infectious Diseases Hospital Muñiz.

Inclusion criteria

- HIV + patients over 18 years old with PPDH

- HIV + patients over 18 with other infectious pathologies contemplated in the differential diagnosis, which were treated at the Mycology Unit of F.J. Muñiz Hospital in the mentioned period.
- Healthy volunteers (no apparent disease).

All patients were required to reside in the Rio de la Plata endemic area of Argentina.

Exclusion criteria

- Patients under 18 years old
- Patients who were not residents of the endemic area
- Patients without characteristic symptoms or clear clinical follow-up
- Patients that had proven coinfections with other etiological agents considered in this study, or treatment confirmed with amphotericin B, itraconazole or fluconazole pre-clinical sampling.

Patients and healthy volunteers

- *Patients with PPDH.* Fifty HIV+ patients were included in this group. A positive case of PPDH was defined as an individual with positive culture and/or histopathological findings of intracellular yeasts and granuloma consistent with this fungal infection and by Gomori-Grocott stains [parameter according to recommendations of the EORCT/MSG Consensus Group] [36].
- *HIV + patients with other infectious pathologies.* Fifty one patients were included: 3 pneumocystosis, 12 cryptococcosis, 1 leishmaniosis, 2 candidemias, 6 tuberculosis, 3 paracoccidioidomycosis, 24 patients with T CD4+ lymphocyte counts <200 cells/ μ l and different pathologies; with no characteristic signs or clinical symptoms, nor epidemiological history or other diagnostic elements of mycosis or tuberculosis (18 with impregnation syndrome and fever, 2 pemphigus vulgaris and 4 febrile neutropenia).
- *Healthy volunteers.* 15 individuals older than 18 years old without apparent diseases.

All demographic and clinical-epidemiological data of the patients were recorded and stored in a database for further analysis.

The diagnosis of HIV infection was determined by EIA serological test and confirmation by the real-time PCR technique to determine the viral load.

The Research Ethics Committee of Hospital Muñiz reviewed and approved the conduct of this study

Clinical samples

The following samples from all individuals meeting the inclusion criteria were analyzed: urine, EDTA anticoagulated peripheral blood, serum and pre-treated blood samples for lysis-centrifugation blood culture.

Tzanck cytodiagnosis was performed in scrapings in all patients who had skin or mucosal lesions.

Samples were taken on the first day and ten days after medical consultation taking into account that no patient had been previously treated with amphotericin B or itraconazole.

Urine samples were stored at -15 °C, serum and whole blood treated with EDTA at 4 °C until the time of their processing. Blood cultures and smears for cytodiagnosis were processed immediately after being collected.

Conventional diagnostic methods

- Blood culture by lysis-centrifugation (BC).* Peripheral blood samples pretreated with 5% saponin and sodium polyanethol sulfonate were cultured on Sabouraud agar and Brain-Heart Infusion agar at 28 °C and 37 °C, according to the technique described by Bianchi et al. [37].
- Tzanck cytodiagnosis.* Scarification with a sterile scalpel was performed in 50 patients who presented skin and mucosal lesions. It was possible to detect the presence of typical elements of the yeast phase of *H. capsulatum* and other etiological agents after Giemsa stain [38,39].

Immunological methods

- Serological tests.* Detection of circulating anti *H. capsulatum* antibodies was performed by agar gel immunodiffusion techniques and counter-immunoelectrophoresis with secondary immunodiffusion in agarose gel (Ac-ID) [40], in serum samples from the 3 groups of patients. The antigen used was an aqueous extract of the yeast phase of *H. capsulatum* [41].

- b. *Antigen detection* (HC-Ag). The presence of *H. capsulatum* galactomannan antigen was determined in urine samples of all patients and healthy volunteers with commercial EIA using monoclonal antibodies HGM 201 (IMMY®, Norman, OK, USA). The used cutoff value was 0.2 ng/ml.

Molecular methods

A nested PCR designed by Bialek et al. and modified by Toranzo et al. was performed in whole blood samples anticoagulated with EDTA, from patients and healthy volunteers.

The primers used make it possible to amplify a DNA sequence that codes for the 100 kDa protein involved in the process of infection and survival of the fungus within the host cell [21,25].

The external primers Hc I (5'-GCG TTC CGA GCC TTC CAC CTC ACC-3') and Hc II (5'-ATG TCC CAT CGG GCG CCG TGT AGT-3') delimit a sequence of 391 bp. The internal primers Hc III (5'-GAC ATC TAG TCG CGG CCA GGT TCA-3') and Hc IV (5'-AGGAGA GAA CTG TAT CGG TGG CTT G-3') delimit a 210 bp sequence.

Statistical analysis

Sensitivity (S), specificity (E), positive predictive value (PPV) and negative predictive value (NPV) with their respective 95% confidence intervals (CI) were evaluated for each of the diagnostic methods used. The latter were: blood culture, antibody detection, PCR in blood and determination of urinary antigen. Statistical parameters were evaluated individually and by combining them using contingency tables. The cases of PPDH were used as reference. The agreement between the methods was analyzed with the Kappa Cohen statistical coefficient and interpretation of the Kappa values was: 0.00-0.20, infinitesimal agreement; 0.21-0.40, little agreement; 0.41-0.60, moderate agreement; 0.61-0.80, good agreement; 0.81-1.00, excellent agreement.

A ROC curve was built to identify one cutoff value according to the urinary antigen study results.

The variables normality was determined with the modified Shapiro-Wilk test, and the homogeneity of variances with the F and the Levene tests. We also analyzed the test of Kruskal-Wallis and Wilcoxon signed-rank test to see if there were any significant differences in the response time (RT), which was defined as the average time between a clinical sample was taken and the result report was emitted by the lab. The programs InfoStat version 2018 [42], EPIDAT 4.2 (Anón sf) and SPSS Statistics 20 were used. It was considered a p value <0.05 as statistically significant.

3. Results

During the study period (24 months) 136 potentially eligible patients diagnosed with PPDH or other pathologies were evaluated. On the other hand, 35 cases were excluded from the analysis: 5 because of coming from outside the area of the Rio de la Plata, 3 immunocompetent, 5 with previous antifungal treatment, 2 had confirmed coinfection with *Cryptococcus neoformans* and 20 patients in which clinical samples required for this study could not be analyzed. In the end, 116 cases were included. One hundred and one patients met the inclusion criteria: 50 cases were PPDH, and 51 cases suffered from other pathologies. Then, 15 apparently healthy volunteers were added (Figure 1). Out of the 116 cases, 83 (71.6%) were men and 33 (28.4%) women, median age was 42 years (interquartile range- IQR: 33-48 years old). From these apparently healthy volunteers and patients, a total of 514 clinical samples were processed: 116 urine, 116 peripheral blood samples, 116 sera, 116 blood cultures and 50 mucosal or skin lesion scrapings analyzed by Tzanck cytodiagnosis.

Demographic and clinical features of HIV+ patients with PPDH

Within the 50 patients with PPDH, 37 were men (74%) and 13 women (26%) with a median age of 40 years (IQR: 34-48 years old). The 100% had CD4+ lymphocyte count <200 cells/ μ l, (median 25 cells/ μ l; IQR: 12-49 cells/ μ l). In 34% (17/50) of the cases, disseminated histoplasmosis was the AIDS marker disease.

Definitive diagnosis was made by the growth of the fungus in blood cultures in 20 cases (40%), by the visualization of *Histoplasma capsulatum* yeasts in the Giemsa stain of mucocutaneous scarification sample in 15 cases (30%) and in other 15 cases (30%) both techniques were positive simultaneously. Regarding tegumentary manifestations, 33 patients with PPDH presented injuries

that were mainly ulcerated skin papules or molluscum-like lesions. Of these, 67% (22/33) were cutaneous and 33% (11/33) mucosal. Most of the skin lesions were found on the thorax and face (90%) and predominated over injuries in the extremities 10% ($\chi^2 = 14.73$; $p = 0.0001$), whereas the 100% of the mucosal lesions were oral. No yeasts were observed in scarification samples of 3 (9.1%) patients.

At the time of consultation, 74% (37/50) of the patients had a pathological chest X-ray. Abnormalities were miliary 70.27% ($n = 26$), interstitial infiltrate 16.22% ($n = 6$), bilateral nodules 10.81% ($n = 4$) and peripheral pulmonary nodules 2.70% ($n = 1$). The miliary pattern appeared in a significantly greater proportion than the other lesions ($\chi^2 = 5.44$; $p = 0.02$).

The established treatment was amphotericin B deoxycholate and itraconazole, depending on the magnitude of the symptoms considered by the treating physician and the general condition of the patients. In some cases, they received both drugs. Patients who were hospitalized at the time of histoplasmosis diagnosis were initially treated with amphotericin B deoxycholate at 0.7 mg/kg/day, amphotericin B lipid complex 5mg/kg/day or liposomal amphotericin B 3 mg/kg/day for 7 or 14 days depending on their clinical status. Only in cases of bone marrow involvement, intestinal obstruction, or meningitis, treatment with amphotericin B was prolonged. In all cases, itraconazole 400 mg/day was indicated after amphotericin B. Treatment with itraconazole at the mentioned dose was maintained for 3 or 6 months depending on the evolution. After this period, they continued with the same medication but with 200 mg/day (secondary prophylaxis) until obtaining two LTCD4+ counts >150 cells/ μ l with an undetectable HIV viral load.

The fatality rate in this group of patients was 14%.

Demographic and clinical characteristics of HIV+ patients with other pathologies

HIV+ patients with other diseases were 38 men (75%) and 13 women (25%), with a median age of 42 years (IQR 32-48 years old). The 97% had CD4+ counts < 200 cells/ μ l (median 68 cells/ μ l; IQR: 36 - 86 cells/ μ l). Eleven patients had skin lesions and 6 mucosal ones. The former were located on the trunk and face (82%), significantly predominating over the limb lesions which were only 18% ($\chi^2 = 4.45$; $p = 0.035$), regarding the mucosal lesions the 100% of them were of nasopharyngeal location. Only in 10 lesions nonspecific inflammation was observed, in two *Paracoccidioides* sp. yeasts, two viral syncytia, 1 *Cryptococcus* sp. yeasts, 1 *Malassezia* sp. and 1 *Molluscum contagiosum*.

The fatality rate in this group of patients was 26%, the percentage was higher than in the group of patients with PPDH, although without significant differences ($\chi^2 = 2.101$; $p = 0.147$)

Sensitivity, specificity, positive predictive value, negative predictive value, and response time of the different methods employed for the diagnosis of PPDH.

The results of S, E, PPV, NPV and the validity index of each of the methods can be observed and compared in Table 1.

The RT of the various methods was 19 days for the BC, 4 days HC-Ag, 5 days for Hcp100 nPCR and 5 days for Ac-ID. Significant differences were observed in RT as the statistical H calculated by the Kruskal-Wallis test was 320.97 ($p < 0.05$). This difference in RT is mainly due to the blood culture as when compared with HC-Ag, Hcp100 nPCR and Ac-ID. By the Wilcoxon signed rank test were obtained the following values of the statistic Z: 9.44; 9.37 and 9.40 ($p < 0.05$) in the 3 comparisons of means (Figure 2).

Analysis of concordance among the different diagnostic methods

The degree of agreement of the HC-Ag with the reference method was 0.920. The results of the degree of agreement among methods (including the reference method) can be seen in Table 2.

ROC curve

It was calculated one cutoff for the HC-Ag technique by a ROC curve that was of 0.39 ng/ml, with S 94.0% (86.4% to 100%) and E 97.0% (92.1% to 100%). Area under the curve and other parameters were determined for this new cutoff value and can be seen in Figure 3.

The statistical parameters of this method for the different cutoff values were compared in Figure 4 and Table 3. Concordance between HC-Ag and the reference method calculated by Cohen's Kappa coefficient, using cut-off values of 0.2 ng/ml (Kappa= 0.920) and 0.39 ng/ml (Kappa= 0.933), was also estimated.

Clinical characteristics of patients with PPDH and false negative results of HC-Ag

6 percent (3/50) of patients with PPDH had false negative results on the HC-Ag. Diagnosis was confirmed through positive BC, in 100% of these cases; *H. capsulatum* grew in an average of 19 days. In all patients of this group the Hcp100 nPCR was negative (0 %) and the Ac-ID determination was positive (100%). Only one had lesions in the oral mucosa, but no intracellular yeasts characteristic of *H. capsulatum* were observed by scraping and subsequent Giemsa stain. Central nervous system histoplasmosis was seen in one patient and *Histoplasma capsulatum* was obtained in CSF culture but both HC-Ag determination and Hcp100 nPCR gave negative results for this clinical sample. The median age of this group of patients was 34 years old (IQR: 28 - 51 years old), all patients were male. All had CD4+ counts <200 cells/ μ l and a median of 74.00 cells/ μ l (IQR: 49.00- 77.00 cells/ μ l). They were initially treated with amphotericin B dc 0.5 mg/kg/day followed by itraconazole 400 mg/day. Lethality rate was 33.3%, higher than that in the group of patients with PPDH with HC-Ag positive results, but without significant differences ($\chi^2 = 0.991$; $p = 0.320$).

Clinical characteristics of patients with pathologies other than PPDH and healthy volunteers with false positive results of HC-Ag

Five percent (3/66) of patients without PPDH and healthy volunteers had a positive result of HC-Ag. Two had paracoccidioidomycosis and one cryptococcosis. The Hcp100 nPCR, BC and Ac-ID methods were negative in all these patients. One patient with paracoccidioidomycosis was the only one in this group who presented mucocutaneous lesions, on the oral mucosa. Multi-budding yeasts compatible with *Paracoccidioides* spp. were found in in Giemsa-stained smears from the scarification. The median age in this group was of 42 years old (IQR: 38-74), all three patients were male. Sixty six percent had CD4+ counts <200 cells/ μ l, median 70 cells/ μ l (IQR: 46-686 cells/ μ l).

None of the patients in this group died, therefore the Lethality rate was 0%.




Figure 1. Inclusion criteria flow chart.

Table 1. Evaluation of the analytical parameters of each of the methods used in this study.

	HC-Ag	Hcp100 nPCR	BC	Ac-ID	HC-Ag + Hcp100 nPCR + Ac-ID
S	94.0% (86.4% a 100.0%)	82.0% (70.3% to 93)	70.0% (56.3 to 83.7%)	26.0% (12.8% to 39.2%)	100% (99% a 100%)
E	95.5% (89,7% a 100.0%)	97.0% (92.8% to 100%)	100% (99.2% to 100%)	100% (99.2% to 100%)	92.4% (85.3% a 99.6%)
PPV	94.0% (86,4% a 100.0%)	95.4% (87.9% to 100%)	100% (98.6% to 100%)	100% (96.2% to 100%)	90.9% (82.4% a 99.4%)

NPV	95.5% (89.7% a 100.0%)	87.7% (79.4% to 95.9%)	81.5% (72.4% to 90.6%)	64.1% (54.3% to 73.8%)	100% (99.2% a 100%)
Validity index	94.8% (90.4% a 99.3%)	90.5% (84.8% to 96.3%)	87.1% (80.5% to 93.6%)	68.1% (59.2% to 77.0%)	95.7% (91,6% a 99,8%)

S: sensitivity, E: specificity, PPV: positive predictive value, NPV: negative predictive value, HC-Ag: determination of urinary *H. capsulatum* antigen by EIA, BC: blood culture, Ac-ID: detection of antibodies, Hcp100 nPCR: nested PCR in whole blood, HC-Ag + Hcp100 nPCR + Ac-ID: is the combination of the HC-Ag, Hcp100 nPCR and Ac-ID methods. Values in parentheses correspond to 95% CIs.




Figure 2. Analysis of response times in days (RT) of each of the methods used in this study. HC-Ag: determination of urinary *H. capsulatum* antigen by EIA, BC: blood culture, Ac-ID: detection of antibodies, Hcp100 nPCR: nested PCR in whole blood, HC-Ag + Hcp100 nPCR + Ac-ID: is the combination of the HC-Ag, Hcp100 nPCR and Ac-ID methods, SD: standard deviation.

Table 2. Analysis of concordance between the different diagnostic methods used in this study calculated with Cohen's Kappa coefficient.

	Hcp100 nPCR	HC-Ag	BC	Ac-ID	PPDH
Hcp100 nPCR	1	0.851	0.715	0.432	0.851
HC-Ag	0.851	1	0.711	0.399	0.920
BC	0.715	0.711	1	0.513	0.794
Ac-ID	0.432	0.399	0.513	1	0.483
PPDH	0.851	0.920	0.794	0.483	1

HC-Ag: urinary *H. capsulatum* antigen determination by EIA, BC: blood culture, Ac-ID: antibody detection, Hcp100 nPCR: nested whole blood PCR, PPDH: Progressive and disseminated histoplasmosis proven.




Figure 3. ROC curve and other parameters of the HC-Ag test. * CV: cutoff values, S: sensitivity, E: specificity, PPV: positive predictive value, NPV: negative predictive value, CVP and CVN: positive and negative likelihood coefficient. Values between brackets correspond to 95% CIs.

Table 3. Comparison of the analytical parameters and the Cohen's Kappa statistic of the HC-Ag method, using the cut-off point of 0.2 ng/ml and 0.39 ng/ml.

	HC-Ag 0.2 ng/ml	HC-Ag 0.39 ng/ml
S	94.0% (86.4% a 100.0%)	94,0% (86.4% to 100%)
E	95.5% (89.7% a 100.0%)	97.0% (92.1% to 100%)
PPV	94.0% (86.4% a 100.0%)	93.8% (85.9% to 100%)
VPN	95.5% (89.7% a 100.0%)	95.9% (89.4% to 100%)
Validity index	94.8% (90.4% a 99.3%)	95.7% (91.6% to 99.8%)
CVP	20.68 (6.83 to 62.61)	31.02 (7.91 to 121.65)
CVN	0.06 (0.02 to 0.19)	0.06 (0.02 to 0.19)
Kappa	0.920	0.933

S: sensitivity, E: specificity, PPV: positive predictive value, NPV: negative predictive value, CVP and CVN: positive and negative likelihood coefficient, HC-Ag 0.2 and HC-Ag 0.39: determination of urinary antigen of *H. capsulatum* by EIA, using cut-off values of 0.2 ng/ml and 0.39 ng/ml. Values between brackets correspond to 95% CIs.




Figure 4. Urinary antigen concentration in ng/ml (HC-Ag) in patients with PPDH, other pathologies and healthy volunteers. CV: cutoff values, HC-Ag: urinary *H. capsulatum* antigen determination by EIA, T CD4+ <200 DP: patients with T CD4+ lymphocyte counts <200 cells/ μ l and different pathologies; with no characteristic signs or clinical symptoms, nor epidemiological history or other diagnostic elements of mycosis or tuberculosis.

4. Discussion

Histoplasmosis is the endemic mycosis of greater impact on public health in Latin America [43], although its true impact is still not known and it is considered a neglected disease by various authors [13,44]. PPDH is associated with HIV infection in 90 to 95% of cases [4,13] and occurs mainly in patients who are not receiving antiretroviral treatment and with a CD4+ cell count <100 cells/ μ l [8,12,16,45–47]. Eighty to 95 % of patients may have a favorable evolution with an early diagnosis and adequate treatment [47]. The case fatality rate in different endemic areas of America averages 30% [12], due to several factors that must be considered in order to design strategies that contribute to reducing the impact of this scourge. Among them: unknown actual incidence as it is not a compulsory notification disease, there is little information related to this mycosis and the scarce number of trained professionals. Clinical manifestations are not very specific and often wrongly diagnosed as tuberculosis or other diseases. Treatment is not always accurate because of economic crisis in many countries and consequent lack of access to liposomal amphotericin B or even itraconazole. Low socio-economic status of Latin American patients and their cultural differences from those of other countries contribute to the poor adherence to antiretroviral and antifungal treatment and, finally delay in diagnosis when rapid and simple methods such as urinary antigen detection, which began to be developed in the US in 1986 [48], are not available. These issues were analyzed in The Manaos Declaration in 2019 [27] where participated 24 countries and whose main objective was to achieve access to rapid diagnostic methods and to treatments with amphotericin B and itraconazole in 100% of Latin American countries by 2025.

Moreover, in Argentina the situation is more serious because 70% of HIV+ patients are living in the endemic area [8,47]. Considering that the prevalence of histoplasmosis is close to 30% in our country, we can estimate that approximately 41,000 HIV+ individuals could be infected with this fungus and suffer a reactivation with the progression of the HIV/AIDS disease [49,50]. According to the Official Bulletin, there was an average of 5,800 new annual cases of HIV infection in the period 2011-2019 [49]. Therefore, an incidence of 100 cases/year of PPDH and consequently about 20 deaths can be estimated, as the prevalence of HIV in this endemic area is about 2.5% with a case fatality rate close to 20% [7,8,23,47].

This estimated number may be even higher since there are 17% HIV+ people who are unaware of their diagnosis and there are also some authors who consider that the prevalence of HP in HIV+ is even higher [8,18,19,47,51,52] and similar to the number of annual deaths caused by tuberculosis in those patients (close to 76 cases in 2019) [53]; and coincident with Adenis et al. publication [20].

In 2007, a HC-Ag urinary kit using polyclonal antibodies developed by the CDC [54] was evaluated first in Guatemala and then in Colombia, on patients with PPDH in HIV+ patients. Its sensitivity was 81% in Guatemala [32] and 86% in Colombia [28] and its global specificity was 95% and 94% respectively. After that, a multicenter study using the HGM, IMMY (with monoclonal antibodies) to evaluate the performance of this kit demonstrated a sensitivity of 98% with the quantitative assay and 95% in the semiquantitative one, on 589 urine samples from patients with PPDH from Colombia and Guatemala [35]. In our research, the HC-Ag with the same kit had a sensitivity of 94% (with both 0.2 ng/ml and 0.39 ng/ml cutoff values) and its specificity reached 97% when 0.39 ng/ml cutoff value established in this research, was used.

False positive HC-Ag results were observed mainly with other mycoses (all cases of paracoccidioidomycosis and 1 cryptococcosis), as it was seen in the mentioned multicenter study [35]. The cut off value established in our research was useful to reduce false positives and improve E, without changing the other parameters.

S and NPV of the HC-Ag test were higher to that of the other diagnostic methods. In 100% of the proven cases where urinary antigen could not be detected (false negatives), the patients had demonstrable antibodies. Moreover, when different rapid diagnostic methods were combined (HC-Ag, Hcp100 nPCR and Ac-ID) both S and NPV reach a performance of 100%.

The time to reach diagnosis has a fundamental impact on patient outcome and survival. Samayoa et al., were able to determine that the average survival time of PPDH patients without treatment was 19 days [2].

In this study, 66% of patients with PPDH had mucocutaneous manifestations which is consistent with data from Latin America [8,16], and differs from those observed in the US where only 6% of patients present this type of lesions [4]. When lesions are accessible; a diagnosis can be obtained in less than 2 hours by Tzanck cytodiagnosis [55].

However, about 30-40 % of patients do not have tegumentary manifestations [43], and in these cases the use of rapid diagnostic methods would be highly recommended since cultures take more than two weeks. When the diagnostic times of the tests were compared by means of the RTs, it was possible to determine that those of HC-Ag, Hcp100 nPCR and Ac-ID were significantly lower than those of BC whose average time was 19 days, coinciding with the average survival time estimated by Samayoa [2].

Lethality rate in patients with PPDH was 14%, lower than that reported in other studies performed in our institution where values averaging 20% were obtained [7,8,16,23,47].

5. Conclusions

The HC-Ag method proved its usefulness in the diagnosis of progressive and disseminated HP and it can be stated that its use and its complementation with conventional and molecular biology methods in mycology laboratories is essential to know the real incidence and prevalence of this pathology, reduce diagnosis times, improve targeted treatment and propose follow-up, prophylaxis and prevention strategies, in order to reduce the lethality rate in HIV+ patients or those with other immunosuppressive pathologies.

This is the first study published in Argentina where a commercial EIA HGM 201 with monoclonal antibodies is used and compared with other methods, and we believe that its implementation has a great contribution in our country and in Latin America since it allows collaborating with the goal set in Manaus for 2025.

Author Contributions: Conceptualization, Emmanuel Marin and Alicia Arechavala; Data curation, Emmanuel Marin; Formal analysis, Emmanuel Marin, Mercedes Romero and Alicia Arechavala; Investigation, Emmanuel Marin, Fernando Messina and Gabriela Santiso; Methodology, Emmanuel Marin, Mercedes Romero and Gabriela Santiso; Software, Emmanuel Marin; Validation, Fernando Messina and Gabriela Santiso; Visualization,

Fernando Messina; Writing – original draft, Emmanuel Marin; Writing – review & editing, Emmanuel Marin, Fernando Messina, Mercedes Romero, Alicia Arechavala, Roxana Depardo and Gabriela Santiso. All authors will be informed about each step of manuscript processing including submission, revision, revision reminder, etc. via emails from our system or assigned Assistant Editor.

Funding: This research received no external funding.

Informed Consent Statement: Patient consent was waived due to the retrospective nature of the study. No data that could allow the identification of the patients were provided.

Data Availability Statement: Data presented in this study are available upon request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Colombo AL, Tobón A, Restrepo A, Queiroz-Telles F, Nucci M. Epidemiology of endemic systemic fungal infections in Latin America. *Med Mycol.* 4 de mayo de 2011;1-14.
2. Samayoa B, Roy M, Medina N, Cleveland AA, Lau-Bonilla D, Scheel CM, et al. High Mortality and Coinfection in a Prospective Cohort of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients with Histoplasmosis in Guatemala. *Am J Trop Med Hyg.* 12 de julio de 2017;97(1):42-8.
3. Nacher M, Adenis A, Mc Donald S, Do Socorro Mendonca Gomes M, Singh S, Lopes Lima I, et al. Disseminated Histoplasmosis in HIV-Infected Patients in South America: A Neglected Killer Continues on Its Rampage. *PLoS Negl Trop Dis.* 21 de noviembre de 2013;7(11):e2319.
4. Negroni R. Histoplasmosis in Latin-America. *Biomédica.* 2011;31(3):301-4.
5. Rubinstein P, Negroni R. Histoplasmosis: en Micosis broncopulmonares del adulto y del niño 2da. Rubinstein P, Negroni R. Rubinstein P, Negroni R editors. Buenos Aires: Editorial Beta SRL; 1981. Pp. 249-290. Editorial Beta SRL. 1981;249-90.
6. Negroni R, Arechavala AI, Maiolo EI. Histoplasmosis clásica en pacientes inmunocomprometidos. *Med Cutan Iber Lat Am.* 2010;38(2):59-69.
7. Corti ME, Negroni R, Esquivel P, Villafañe MF. Histoplasmosis diseminada en pacientes con SIDA: análisis epidemiológico, clínico, microbiológico e inmunológico de 26 pacientes. :8.
8. Daneri AGL, Arechavala A, Iovannitti CA, Mujica MT. Histoplasmosis diseminada en pacientes HIV/SIDA. Buenos Aires, 2009-2014. 2016;6.
9. Durkin MM, Connolly PA, Karimi K, Wheat E, Schnizlein-Bick C, Allen SD, et al. Pathogenic Differences between North American and Latin American Strains of *Histoplasma capsulatum* var. *capsulatum* in Experimentally Infected Mice. *J Clin Microbiol.* 1 de septiembre de 2004;42(9):4370-3.
10. Karimi K, Wheat LJ, Connolly P, Cloud G, Hajjeh R, Wheat E, et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. *J Infect Dis.* 1 de diciembre de 2002;186(11):1655-60.
11. Kauffman CA. Histoplasmosis: a Clinical and Laboratory Update. *Clin Microbiol Rev.* enero de 2007;20(1):115-32.
12. Cano-Torres JO, Olmedo-Reneau A, Esquivel-Sánchez JM, Camiro-Zuñiga A, Pérez-Carrisoza A, Madrigal-Iberri C, et al. Progressive disseminated histoplasmosis in Latin America and the Caribbean in people receiving highly active antiretroviral therapy for HIV infection: A systematic review. *Med Mycol.* 1 de octubre de 2019;57(7):791-9.
13. Adenis AA, Aznar C, Couppié P. Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps. *Curr Trop Med Rep [Internet].* 28 de marzo de 2014 [citado 4 de junio de 2020]; Disponible en: <http://link.springer.com/10.1007/s40475-014-0017-8>
14. Dantas KC, Freitas RS de, da Silva MV, Criado PR, Luiz O do C, Vicentini AP. Comparison of diagnostic methods to detect *Histoplasma capsulatum* in serum and blood samples from AIDS patients. Ito E, editor. *PLOS ONE.* 17 de enero de 2018;13(1):e0190408.
15. Garbee DD, Pierce SS, Manning J. Opportunistic Fungal Infections in Critical Care Units. *Crit Care Nurs Clin North Am.* marzo de 2017;29(1):67-79.
16. Frola C, Bermejo V, Spadaccini L, Guelfand L, Pérez H. Impacto de la histoplasmosis diseminada en pacientes HIV positivos. 2013;5.
17. Wheat J. Endemic Mycoses in AIDS: a Clinical Review. *CLIN MICROBIOL REV.* 1995;8:14.
18. Pietrobbon D, Negro-Marquinez L, Kilstein J, Galíndez J, Greca A, Battagliotti C. [Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment]. *Enferm Infecc Microbiol Clin.* marzo de 2004;22(3):156-9.
19. The neglected histoplasmosis in Latin America Group. Disseminated histoplasmosis in Central and South America, the invisible elephant: the lethal blind spot of international health organizations. *AIDS.* enero de 2016;30(2):167-70.

20. Adenis AA, Valdes A, Cropet C, McCotter OZ, Derado G, Couppie P, et al. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study. *Lancet Infect Dis*. 2018;18(10):1150-9.
21. Toranzo AI, Tiraboschi IN, Fernández N, Ibarra-Camou B, Rivas MC, Lee W, et al. Diagnóstico molecular de histoplasmosis humana en muestras de sangre entera. *Rev Argent Microbiol*. 2009;7.
22. Fandiño-Devia E, Rodríguez-Echeverri C, Cardona-Arias J, Gonzalez A. Antigen Detection in the Diagnosis of Histoplasmosis: A Meta-analysis of Diagnostic Performance. *Mycopathologia*. abril de 2016;181(3-4):197-205.
23. Messina FA, Corti M, Negroni R, Arechavala A, Bianchi M, Santiso G. [Histoplasmosis in AIDS patients without tegumentary manifestations]. *Rev Chil Infectologia Organismo Of Soc Chil Infectologia*. 2018;35(5):560-5.
24. Zatti M da S, Arantes TD, Fernandes JAL, Bay MB, Milan EP, Naliato GFS, et al. Loop-mediated Isothermal Amplification and nested PCR of the Internal Transcribed Spacer (ITS) for *Histoplasma capsulatum* detection. *PLoS Negl Trop Dis* [Internet]. 26 de agosto de 2019 [citado 21 de mayo de 2021];13(8). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6730939/>
25. Bialek R, Feucht A, Aepinus C, Just-Nübling G, Robertson VJ, Knobloch J, et al. Evaluation of two nested PCR assays for detection of *Histoplasma capsulatum* DNA in human tissue. *J Clin Microbiol*. mayo de 2002;40(5):1644-7.
26. Buitrago MJ, Martín-Gómez MT. Timely Diagnosis of Histoplasmosis in Non-endemic Countries: A Laboratory Challenge. *Front Microbiol*. 2020;11:467.
27. Caceres DH, Adenis A, de Souza JVB, Gomez BL, Cruz KS, Pasqualotto AC, et al. The Manaus Declaration: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group. *Curr Fungal Infect Rep*. 1 de diciembre de 2019;13(4):244-9.
28. Caceres DH, Scheel CM, Tobón AM, Ahlquist Cleveland A, Restrepo A, Brandt ME, et al. Validation of an enzyme-linked immunosorbent assay that detects *Histoplasma capsulatum* antigenuria in Colombian patients with AIDS for diagnosis and follow-up during therapy. *Clin Vaccine Immunol*. septiembre de 2014;21(9):1364-8.
29. Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. *Infect Dis Clin North Am*. marzo de 2016;30(1):207-27.
30. Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of *Histoplasma capsulatum* antigen in serum and urine specimens. *N Engl J Med*. 9 de enero de 1986;314(2):83-8.
31. Williams B, Fojtasek M, Connolly-Stringfield P, Wheat J. Diagnosis of histoplasmosis by antigen detection during an outbreak in Indianapolis, Ind. *Arch Pathol Lab Med*. diciembre de 1994;118(12):1205-8.
32. Scheel CM, Samayoa B, Herrera A, Lindsley MD, Benjamin L, Reed Y, et al. Development and Evaluation of an Enzyme-Linked Immunosorbent Assay To Detect *Histoplasma capsulatum* Antigenuria in Immunocompromised Patients. *Clin Vaccine Immunol*. junio de 2009;16(6):852-8.
33. Theel ES, Harring JA, Dababneh AS, Rollins LO, Bestrom JE, Jespersen DJ. Reevaluation of commercial reagents for detection of *Histoplasma capsulatum* antigen in urine. *J Clin Microbiol*. abril de 2015;53(4):1198-203.
34. Zhang X, Gibson B, Daly TM. Evaluation of Commercially Available Reagents for Diagnosis of Histoplasmosis Infection in Immunocompromised Patients. *J Clin Microbiol*. 1 de diciembre de 2013;51(12):4095-101.
35. Cáceres DH, Samayoa BE, Medina NG, Tobón AM, Guzmán BJ, Mercado D, et al. Multicenter Validation of Commercial Antigenuria Reagents To Diagnose Progressive Disseminated Histoplasmosis in People Living with HIV/AIDS in Two Latin American Countries. *J Clin Microbiol*. 2018;56(6).
36. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis* 2008;46:1813-21
37. Bianchi M, Robles AM, Vitale R, Helou S, Arechavala A, Negroni R. The usefulness of blood culture in diagnosing HIV-related systemic mycoses: evaluation of a manual lysis centrifugation method. *Med Mycol*. 2000;4.
38. Bianchi MH, Santiso GM, Lehmann EA, Walker LG, Arechavala AI, Maiolo EI, et al. Utilidad del citodiagnóstico de Tzanck en un hospital de enfermedades infecciosas de la ciudad de Buenos Aires. *Dermatol Argent*. 30 de mayo de 2012;18(2):42-6.
39. A. Tzanck. Le cytodiagnostics immediate en dermatologie. *Bull Soc Fr Dermatol Syph*. 1947;7:68-70.

40. Arechavala A, Robles AM, Negroni R, Bianchi M, Taborda A. Valor de los métodos directos e indirectos de diagnóstico de las micosis sistémicas asociadas al SIDA. *Rev Inst Med Trop São Paulo*. 35:163-9.
41. Negroni R, Iovannitti CA, Arechavala A, Carnovale S, Kumiko E. Preparación y estudio de un exo antígeno de la fase levaduriforme de *Histoplasma capsulatum* para reacciones serológicas. 1998;15:282-5.
42. Di Rienzo JA, Casanoves F, Balzarini MG, Gonzalez L, Tablada M, Robledo CW. InfoStat versión 2018. Centro de Transferencia InfoStat, FCA, Universidad Nacional de Córdoba, Argentina. Disponible en: <http://www.infostat.com.ar>
43. Gómez BL. Histoplasmosis: Epidemiology in Latin America. *Curr Fungal Infect Rep*. 19 de octubre de 2011;5(4):199.
44. Nacher M, Couppié P, Epelboin L, Djossou F, Demar M, Adenis A. Disseminated Histoplasmosis: Fighting a neglected killer of patients with advanced HIV disease in Latin America. *PLOS Pathog*. 14 de mayo de 2020;16(5):e1008449.
45. Caceres DH, Tobón AM, Restrepo A, Brandt ME, Chiller T, Berbesi DY, et al. Clinical and Laboratory Profile of Persons Living with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome and Histoplasmosis from a Colombian Hospital. *Am J Trop Med Hyg*. 5 de octubre de 2016;95(4):918-24.
46. Damasceno LS, Ramos AN, Alencar CH, Gonçalves MVF, de Mesquita JRL, Soares ATD, et al. Disseminated histoplasmosis in HIV-infected patients: determinants of relapse and mortality in a north-eastern area of Brazil. *Mycoses*. julio de 2014;57(7):406-13.
47. Negroni R, Messina F, Arechavala A, Santiso G, Bianchi M. [Efficacy of the treatment and secondary antifungal prophylaxis in AIDS-related histoplasmosis. Experience at the Francisco J. Muñiz Infectious Diseases Hospital in Buenos Aires]. *Rev Iberoam Micol*. junio de 2017;34(2):94-8.
48. Wheat LJ, Slama TG, Zeckel ML. Histoplasmosis in the acquired immune deficiency syndrome. *Am J Med*. febrero de 1985;78(2):203-10.
49. Banco de Recursos de Comunicación del Ministerio de Salud de la Nación | Boletín sobre el VIH, sida e ITS en la Argentina N° 37 [Internet]. [citado 21 de julio de 2021]. Disponible en: <https://bancos.salud.gob.ar/recurso/boletin-sobre-el-vih-sida-e-its-en-la-argentina-ndeg-37>
50. Bava AJ. Histoplasmosis in the Muñiz Hospital of Buenos Aires. *Rev Inst Med Trop Sao Paulo*. Diciembre de 1995; 37(6):531-5.
51. Pasqualotto AC, Quieroz-Telles F. Histoplasmosis dethrones tuberculosis in Latin America. *Lancet Infect Dis*. 1 de octubre de 2018;18(10):1058-60.
52. Falci DR, Monteiro AA, Braz Caurio CF, Magalhães TCO, Xavier MO, Basso RP, et al. Histoplasmosis, An Underdiagnosed Disease Affecting People Living With HIV/AIDS in Brazil: Results of a Multicenter Prospective Cohort Study Using Both Classical Mycology Tests and Histoplasma Urine Antigen Detection. *Open Forum Infect Dis* [Internet]. 1 de abril de 2019 [citado 4 de junio de 2020];6(4). Disponible en: <https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofz073/5319214>
53. Banco de Recursos de Comunicación del Ministerio de Salud de la Nación | Boletín sobre Tuberculosis en Argentina No 4 [Internet]. [citado 21 de julio de 2021]. Disponible en: <https://bancos.salud.gob.ar/recurso/boletin-sobre-tuberculosis-en-argentina-no-4>
54. Lindsley MD, Holland HL, Bragg SL, Hurst SF, Wannemuehler KA, Morrison CJ. Production and evaluation of reagents for detection of *Histoplasma capsulatum* antigenuria by enzyme immunoassay. *Clin Vaccine Immunol*. 2007 Jun;14(6):700-9. doi: 10.1128/CVI.00083-07. Epub 2007 Apr 11. PMID: 17428951; PMCID: PMC1951087.
55. Messina FA. Histoplasmosis en pacientes con sida sin manifestaciones tegumentarias. 2014 [citado 15 de octubre de 2020]; Disponible en: <http://repositorio.unne.edu.ar/xmlui/handle/123456789/464>

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.